Skip to main content

Advertisement

SpringerLink
Log in

Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration

  • Review Article
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

The concept of gliodegenerative diseases has not been widely established although there is accumulating evidence that glial cells may represent a primary target of degenerative disease processes. In the central nervous system (CNS), examples that provide a “proof of concept” include at least one alpha-synucleinopathy, multiple system atrophy (MSA), but this disease is conventionally discussed under the heading of “neurodegeneration”. Additional evidence in support of primary glial affection has been reported in neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease and transmissible spongiform encephalopathies. Based on biochemical, genetic and transcriptomic studies it is also becoming increasingly clear that the molecular changes measured in whole tissue extracts, e.g. obtained from Parkinson’s disease brain, are not based on a purely neuronal contribution. This important evidence has been missed in cell culture or laser capture work focusing on the neuronal cell population. Studies of animal and in vitro models of disease pathogenesis additionally suggest glial accountability for some CNS degenerative processes. This review provides a critical analysis of the evidence available to date in support of the concept of gliodegeneration, which we propose to represent an essential although largely disregarded component of the spectrum of classical “neurodegeneration”. Examples from the spectrum of alpha-synucleinopathies are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421

    PubMed  CAS  Google Scholar 

  2. Allan SM, Rothwell NJ (2001) Cytokines and acute neurodegeneration. Nat Rev Neurosci 2:734–744

    PubMed  CAS  Google Scholar 

  3. Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S, Beach T, Rogers J, Schwab C, McGeer PL (2001) Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 101:167–173

    CAS  Google Scholar 

  4. Arima K, Nakamura M, Sunohara N, Ogawa M, Anno M, Izumiyama Y, Hirai S, Ikeda K (1997) Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathol (Berl) 93:558–566

    CAS  Google Scholar 

  5. Arima K, Ueda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (1998) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol (Berl) 96:439–444

    CAS  Google Scholar 

  6. Banati RB, Myers R, Kreutzberg GW (1997) PK (‘peripheral benzodiazepine’)—binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 26:77–82

    PubMed  CAS  Google Scholar 

  7. Barcia C, Sanchez BA, Fernandez-Villalba E, Bautista V, Poza YP, Fernandez-Barreiro A, Hirsch EC, Herrero MT (2004) Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46:402–409

    PubMed  Google Scholar 

  8. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP (1995) Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA 92:9328–9332

    PubMed  CAS  Google Scholar 

  9. Bartzokis G (2004) Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease. Neurobiol Aging 25:5–18

    PubMed  CAS  Google Scholar 

  10. Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, Donnan GA, Howells DW (1999) Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 19:1708–1716

    PubMed  CAS  Google Scholar 

  11. Batchelor PE, Porritt MJ, Martinello P, Parish CL, Liberatore GT, Donnan GA, Howells DW (2002) Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. Mol Cell Neurosci 21:436–453

    PubMed  CAS  Google Scholar 

  12. Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M, Verderio C (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174:7268–7277

    PubMed  CAS  Google Scholar 

  13. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202:17–20

    PubMed  CAS  Google Scholar 

  14. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172:151–154

    PubMed  CAS  Google Scholar 

  15. Braak H, Del TK (2004) Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 25:19–23

    PubMed  CAS  Google Scholar 

  16. Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jakala P, Beyreuther K, Masters CL, Li QX (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson’s disease. J Neurochem 76:87–96

    PubMed  CAS  Google Scholar 

  17. Cardenas H, Bolin LM (2003) Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice. Brain Res 985:89–97

    PubMed  CAS  Google Scholar 

  18. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 149:2736–2741

    PubMed  CAS  Google Scholar 

  19. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064

    PubMed  Google Scholar 

  20. Cheng B, Christakos S, Mattson MP (1994) Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 12:139–153

    PubMed  CAS  Google Scholar 

  21. Combarros O, Infante J, Llorca J, Berciano J (2003) Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord 18:1385–1386

    PubMed  Google Scholar 

  22. Conde JR, Streit WJ (2006) Microglia in the aging brain. J Neuropathol Exp Neurol 65:199–203

    PubMed  Google Scholar 

  23. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2:14

    PubMed  Google Scholar 

  24. Croisier E, Mres DE, Deprez M, Goldring K, Dexter DT, Pearce RK, Graeber MB, Roncaroli F (2006) Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol Appl Neurobiol 32:351–356

    PubMed  CAS  Google Scholar 

  25. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson’s disease mice model. Neurodegeneration 5:137–143

    PubMed  CAS  Google Scholar 

  26. Dabir DV, Trojanowski JQ, Richter-Landsberg C, Lee VM, Forman MS (2004) Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. Am J Pathol 164:155–166

    PubMed  CAS  Google Scholar 

  27. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8:752–758

    PubMed  CAS  Google Scholar 

  28. Dickson DW (2005) Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol (Berl) 109:14–24

    Google Scholar 

  29. Dickson DW, Lin W, Liu WK, Yen SH (1999) Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 9:721–732

    Article  PubMed  CAS  Google Scholar 

  30. Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D’Amato C, Albin R, Gilman S, Yen SH (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 155:1241–1251

    PubMed  CAS  Google Scholar 

  31. Dodel RC, Lohmuller F, Du Y, Eastwood B, Gocke P, Oertel WH, Gasser T (2001) A polymorphism in the intronic region of the IL-1alpha gene and the risk for Parkinson’s disease. Neurology 56:982–983

    PubMed  CAS  Google Scholar 

  32. Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni I, Hurtig HI, Stern MB, Gollomp SM, Grossman M, Lee VM, Trojanowski JQ (2000) Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 59:830–841

    PubMed  CAS  Google Scholar 

  33. Ferger B, Leng A, Mura A, Hengerer B, Feldon J (2004) Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89:822–833

    PubMed  CAS  Google Scholar 

  34. Ferrer I, Blanco R, Carmona M, Puig B (2001) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108:1397–1415

    PubMed  CAS  Google Scholar 

  35. Flugel A, Bradl M, Kreutzberg GW, Graeber MB (2001) Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res 66:74–82

    PubMed  CAS  Google Scholar 

  36. Foltynie T, Lewis SG, Goldberg TE, Blackwell AD, Kolachana BS, Weinberger DR, Robbins TW, Barker RA (2005) The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease. J Neurol 252:833–838

    PubMed  CAS  Google Scholar 

  37. Forno LS (1969) Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 17:557–575

    PubMed  CAS  Google Scholar 

  38. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ (2000) Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 157:361–368

    PubMed  CAS  Google Scholar 

  39. Gandhi S, Muqit MM, Stanyer L, Healy DG, bou-Sleiman PM, Hargreaves I, Heales S, Ganguly M, Parsons L, Lees AJ, Latchman DS, Holton JL, Wood NW, Revesz T (2006) PINK1 protein in normal human brain and Parkinson’s disease. Brain 129:1720–1731

    PubMed  CAS  Google Scholar 

  40. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, Turkheimer F, Good CD, Mathias CJ, Quinn N, Schwarz J, Brooks DJ (2003) [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61:686–689

    PubMed  CAS  Google Scholar 

  41. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2005) In vivo imaging of microglial activation with [(11)C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412

    Google Scholar 

  42. Goedert M, Spillantini MG (1998) Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry 3:462–465

    PubMed  CAS  Google Scholar 

  43. Graeber MB, Bise K, Mehraein P (1994) CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol Appl Neurobiol 20:406–408

    Article  PubMed  CAS  Google Scholar 

  44. Graeber MB, Blakemore WF, Kreutzberg GW (2002) Cellular pathology of the central nervous system. In: Graham DI, Lantos PL (eds) Greenfield’s neuropathology, 7th edn. Edward Arnold, London, pp 123–191

    Google Scholar 

  45. Haik S, Privat N, Adjou KT, Sazdovitch V, Dormont D, Duyckaerts C, Hauw JJ (2002) Alpha-synuclein-immunoreactive deposits in human and animal prion diseases. Acta Neuropathol (Berl) 103:516–520

    CAS  Google Scholar 

  46. Hakansson A, Melke J, Westberg L, Shahabi HN, Buervenich S, Carmine A, Klingborg K, Grundell MB, Schulhof B, Holmberg B, Ahlberg J, Eriksson E, Sydow O, Olson L, Johnels B, Nissbrandt H (2003) Lack of association between the BDNF Val66Met polymorphism and Parkinson’s disease in a Swedish population. Ann Neurol 53:823

    PubMed  Google Scholar 

  47. Hakansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, Sydow O, Olson L, Johnels B, Eriksson E, Nissbrandt H (2005) Investigation of genes coding for inflammatory components in Parkinson’s disease. Mov Disord 20:569–573

    PubMed  Google Scholar 

  48. Hakansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, Sydow O, Olson L, Johnels B, Eriksson E, Nissbrandt H (2005) Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 133:88–92

    PubMed  Google Scholar 

  49. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H (1991) Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 40:445–452

    PubMed  CAS  Google Scholar 

  50. Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378–384

    Article  PubMed  CAS  Google Scholar 

  51. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187–193

    PubMed  CAS  Google Scholar 

  52. Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2001) Widespread occurrence of argyrophilic glial inclusions in Parkinson’s disease. Neuropathol Appl Neurobiol 27:362–372

    PubMed  CAS  Google Scholar 

  53. Hishikawa N, Hashizume Y, Ujihira N, Okada Y, Yoshida M, Sobue G (2003) Alpha-synuclein-positive structures in association with diffuse neurofibrillary tangles with calcification. Neuropathol Appl Neurobiol 29:280–287

    PubMed  CAS  Google Scholar 

  54. Hishikawa N, Hashizume Y, Yoshida M, Niwa J, Tanaka F, Sobue G (2005) Tuft-shaped astrocytes in Lewy body disease. Acta Neuropathol (Berl) 109:373–380

    Google Scholar 

  55. Ho A, Blum M (1997) Regulation of astroglial-derived dopaminergic neurotrophic factors by interleukin-1 beta in the striatum of young and middle-aged mice. Exp Neurol 148:348–359

    PubMed  CAS  Google Scholar 

  56. Hong CJ, Liu HC, Liu TY, Lin CH, Cheng CY, Tsai SJ (2003) Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson’s disease and age of onset. Neurosci Lett 353:75–77

    PubMed  CAS  Google Scholar 

  57. Hosokawa M, Klegeris A, Maguire J, McGeer PL (2003) Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia 42:417–423

    PubMed  Google Scholar 

  58. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72:355–363

    PubMed  CAS  Google Scholar 

  59. Hurley SD, O’Banion MK, Song DD, Arana FS, Olschowka JA, Haber SN (2003) Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp Neurol 184:659–668

    PubMed  CAS  Google Scholar 

  60. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol (Berl) 106:518–526

    CAS  Google Scholar 

  61. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol (Berl) 106:518–526

    CAS  Google Scholar 

  62. Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2005) Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol (Berl) 109:141–150

    CAS  Google Scholar 

  63. Infante J, Llorca J, Berciano J, Combarros O (2005) Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci 228:11–13

    PubMed  CAS  Google Scholar 

  64. Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22:317–330

    PubMed  Google Scholar 

  65. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63:43–52

    PubMed  Google Scholar 

  66. Jellinger KA (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14:153–197

    Article  PubMed  CAS  Google Scholar 

  67. Jellinger KA (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18(Suppl 6):S2–S12

    PubMed  Google Scholar 

  68. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, Fuss B, Mallon B, Macklin WB, Fujiwara H, Hasegawa M, Iwatsubo T, Kretzschmar HA, Haass C (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3:583–588

    PubMed  CAS  Google Scholar 

  69. Kato S, Nakamura H, Hirano A, Ito H, Llena JF, Yen SH (1991) Argyrophilic ubiquitinated cytoplasmic inclusions of Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol (Berl) 82:488–493

    CAS  Google Scholar 

  70. Kato S, Shinozawa T, Takikawa M, Kato M, Hirano A, Awaya A, Ohama E (2000) Midkine, a new neurotrophic factor, is present in glial cytoplasmic inclusions of multiple system atrophy brains. Acta Neuropathol (Berl) 100:481–489

    CAS  Google Scholar 

  71. Komori T (1999) Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick’s disease. Brain Pathol 9:663–679

    Article  PubMed  CAS  Google Scholar 

  72. Kosel S, Egensperger R, von EU, Mehraein P, Graeber MB (1997) On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol (Berl) 93:105–108

    CAS  Google Scholar 

  73. Lantos PL (1992) From slow virus to prion: a review of transmissible spongiform encephalopathies. Histopathology 20:1–11

    PubMed  CAS  Google Scholar 

  74. Li R, Johnson AB, Salomons G, Goldman JE, Naidu S, Quinlan R, Cree B, Ruyle SZ, Banwell B, D’Hooghe M, Siebert JR, Rolf CM, Cox H, Reddy A, Gutierrez-Solana LG, Collins A, Weller RO, Messing A, van der Knaap MS, Brenner M (2005) Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol 57:310–326

    PubMed  Google Scholar 

  75. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O’Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370

    PubMed  CAS  Google Scholar 

  76. Loughlin AJ, Woodroofe MN, Cuzner ML (1993) Modulation of interferon-gamma-induced major histocompatibility complex class II and Fc receptor expression on isolated microglia by transforming growth factor-beta 1, interleukin-4, noradrenaline and glucocorticoids. Immunology 79:125–130

    PubMed  CAS  Google Scholar 

  77. Marner L, Nyengaard JR, Tang Y, Pakkenberg B (2003) Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol 462:144–152

    PubMed  Google Scholar 

  78. Masaki T, Matsushita S, Arai H, Takeda A, Itoyama Y, Mochizuki H, Kamakura K, Ohara S, Higuchi S (2003) Association between a polymorphism of brain-derived neurotrophic factor gene and sporadic Parkinson’s disease. Ann Neurol 54:276–277

    PubMed  CAS  Google Scholar 

  79. Matsuo A, Akiguchi I, Lee GC, McGeer EG, McGeer PL, Kimura J (1998) Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 153:735–744

    PubMed  CAS  Google Scholar 

  80. Matsuzaki M, Hasegawa T, Takeda A, Kikuchi A, Furukawa K, Kato Y, Itoyama Y (2004) Histochemical features of stress-induced aggregates in alpha-synuclein overexpressing cells. Brain Res 1004:83–90

    PubMed  CAS  Google Scholar 

  81. Mattiace LA, Davies P, Dickson DW (1990) Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am J Pathol 136:1101–1114

    PubMed  CAS  Google Scholar 

  82. Mattila KM, Rinne JO, Lehtimaki T, Roytta M, Ahonen JP, Hurme M (2002) Association of an interleukin 1B gene polymorphism (-511) with Parkinson’s disease in Finnish patients. J Med Genet 39:400–402

    PubMed  CAS  Google Scholar 

  83. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291

    PubMed  CAS  Google Scholar 

  84. McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl) 76:550–557

    CAS  Google Scholar 

  85. McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54:599–604

    PubMed  CAS  Google Scholar 

  86. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124

    PubMed  CAS  Google Scholar 

  87. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R (2001) Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol (Berl) 101:249–255

    CAS  Google Scholar 

  88. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150

    PubMed  CAS  Google Scholar 

  89. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208–210

    PubMed  CAS  Google Scholar 

  90. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, Toda T (2002) Association studies of multiple candidate genes for Parkinson’s disease using single nucleotide polymorphisms. Ann Neurol 51:133–136

    PubMed  CAS  Google Scholar 

  91. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109–142

    PubMed  CAS  Google Scholar 

  92. Morale MC, Serra PA, Delogu MR, Migheli R, Rocchitta G, Tirolo C, Caniglia S, Testa N, L’Episcopo F, Gennuso F, Scoto GM, Barden N, Miele E, Desole MS, Marchetti B (2004) Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J 18:164–166

    PubMed  CAS  Google Scholar 

  93. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 176:98–104

    PubMed  CAS  Google Scholar 

  94. Moynagh PN (2005) The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat 207:265–269

    PubMed  CAS  Google Scholar 

  95. Munoz DG (1999) Stains for the differential diagnosis of degenerative dementias. Biotech Histochem 74:311–320

    PubMed  CAS  Google Scholar 

  96. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314–1318

    PubMed  CAS  Google Scholar 

  97. Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kuno S (2000) Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson’s disease. Neurosci Lett 284:73–76

    PubMed  CAS  Google Scholar 

  98. Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kaji R, Kuno S (2001) Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson’s disease. Neurosci Lett 311:1–4

    PubMed  CAS  Google Scholar 

  99. Nishimura M, Kawakami H, Komure O, Maruyama H, Morino H, Izumi Y, Nakamura S, Kaji R, Kuno S (2002) Contribution of the interleukin-1beta gene polymorphism in multiple system atrophy. Mov Disord 17:808–811

    PubMed  Google Scholar 

  100. Nishimura M, Kawakami H, Komure O, Maruyama H, Morino H, Izumi Y, Nakamura S, Kaji R, Kuno S (2002) Contribution of the interleukin-1beta gene polymorphism in multiple system atrophy. Mov Disord 17:808–811

    PubMed  Google Scholar 

  101. Nishimura M, Kuno S, Kaji R, Kawakami H (2005) Influence of a tumor necrosis factor gene polymorphism in Japanese patients with multiple system atrophy. Neurosci Lett 374:218–221

    PubMed  CAS  Google Scholar 

  102. Nishimura M, Kuno S, Kaji R, Yasuno K, Kawakami H (2005) Glutathione-S-transferase-1 and interleukin-1beta gene polymorphisms in Japanese patients with Parkinson’s disease. Mov Disord 20:901–902

    PubMed  Google Scholar 

  103. Ogura K, Ogawa M, Yoshida M (1994) Effects of ageing on microglia in the normal rat brain: immunohistochemical observations. Neuroreport 5:1224–1226

    PubMed  CAS  Google Scholar 

  104. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175

    PubMed  CAS  Google Scholar 

  105. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175

    PubMed  CAS  Google Scholar 

  106. Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen P Sr, Alafuzoff I (1999) Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathol (Berl) 97:383–392

    CAS  Google Scholar 

  107. Oyanagi S, Rorke LB, Katz M, Koprowski H (1971) Histopathology and electron microscopy of three cases of subacute sclerosing panencephalitis (SSPE). Acta Neuropathol (Berl) 18:58–73

    CAS  Google Scholar 

  108. Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, Healy DG, Wood NW, Lees AJ, Holton JL, Revesz T (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657–2671

    PubMed  Google Scholar 

  109. Panek RB, Benveniste EN (1995) Class II MHC gene expression in microglia. Regulation by the cytokines IFN-gamma, TNF-alpha, and TGF-beta. J Immunol 154:2846–2854

    PubMed  CAS  Google Scholar 

  110. Papp MI, Lantos PL (1992) Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 107:172–182

    PubMed  CAS  Google Scholar 

  111. Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79–100

    PubMed  CAS  Google Scholar 

  112. Parkkinen L, Soininen H, Laakso M, Alafuzoff I (2001) Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27:314–325

    PubMed  CAS  Google Scholar 

  113. Perry RH, Irving D, Tomlinson BE (1990) Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 100:223–233

    PubMed  CAS  Google Scholar 

  114. Perry VH, Matyszak MK, Fearn S (1993) Altered antigen expression of microglia in the aged rodent CNS. Glia 7:60–67

    PubMed  CAS  Google Scholar 

  115. Peters A, Sethares C (2002) Aging and the myelinated fibers in prefrontal cortex and corpus callosum of the monkey. J Comp Neurol 442:277–291

    PubMed  Google Scholar 

  116. Piao YS, Wakabayashi K, Hayashi S, Yoshimoto M, Takahashi H (2000) Aggregation of alpha-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Clin Neuropathol 19:163–169

    PubMed  CAS  Google Scholar 

  117. Piao YS, Mori F, Hayashi S, Tanji K, Yoshimoto M, Kakita A, Wakabayashi K, Takahashi H (2003) Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. Acta Neuropathol (Berl) 105:403–409

    Google Scholar 

  118. Polito A, Reynolds R (2005) NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult central nervous system. J Anat 207:707–716

    PubMed  Google Scholar 

  119. Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA (2005) alpha-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20:898–906

    PubMed  CAS  Google Scholar 

  120. Quilty MC, King AE, Gai WP, Pountney DL, West AK, Vickers JC, Dickson TC (2005) Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp Neurol 199(2):249–256

    PubMed  Google Scholar 

  121. Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM (2000) alpha-Synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res 62:9–14

    PubMed  CAS  Google Scholar 

  122. Ross OA, O’Neill C, Rea IM, Lynch T, Gosal D, Wallace A, Curran MD, Middleton D, Gibson JM (2004) Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson’s disease in the Irish. Hum Immunol 65:340–346

    PubMed  CAS  Google Scholar 

  123. Rossi D, Brambilla L, Valori CF, Crugnola A, Giaccone G, Capobianco R, Mangieri M, Kingston AE, Bloc A, Bezzi P, Volterra A (2005) Defective TNFalpha-dependent control of astrocyte glutamate release in a transgenic mouse model of Alzheimer’s disease. J Biol Chem 280(51):42088–42096

    PubMed  CAS  Google Scholar 

  124. Rozemuller AJ, Eikelenboom P, Theeuwes JW, Jansen Steur EN, de Vos RA (2000) Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol (Berl) 100:701–708

    CAS  Google Scholar 

  125. Rozovsky I, Finch CE, Morgan TE (1998) Age-related activation of microglia and astrocytes: in vitro studies show persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiol Aging 19:97–103

    PubMed  CAS  Google Scholar 

  126. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654

    PubMed  CAS  Google Scholar 

  127. Sandell JH, Peters A (2003) Disrupted myelin and axon loss in the anterior commissure of the aged rhesus monkey. J Comp Neurol 466:14–30

    PubMed  Google Scholar 

  128. Satoh J, Muramatsu H, Moretto G, Muramatsu T, Chang HJ, Kim ST, Cho JM, Kim SU (1993) Midkine that promotes survival of fetal human neurons is produced by fetal human astrocytes in culture. Brain Res Dev Brain Res 75:201–205

    PubMed  CAS  Google Scholar 

  129. Schofield E, Kersaitis C, Shepherd CE, Kril JJ, Halliday GM (2003) Severity of gliosis in Pick’s disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain 126:827–840

    PubMed  Google Scholar 

  130. Schulte T, Schols L, Muller T, Woitalla D, Berger K, Kruger R (2002) Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson’s disease. Neurosci Lett 326:70–72

    PubMed  CAS  Google Scholar 

  131. Shavali S, Carlson EC, Swinscoe JC, Ebadi M (2004) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells. J Neurosci Res 76:563–571

    PubMed  CAS  Google Scholar 

  132. Sheffield LG, Berman NE (1998) Microglial expression of MHC class II increases in normal aging of nonhuman primates. Neurobiol Aging 19:47–55

    PubMed  CAS  Google Scholar 

  133. Simmons ML, Murphy S (1992) Induction of nitric oxide synthase in glial cells. J Neurochem 59:897–905

    PubMed  CAS  Google Scholar 

  134. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 251:205–208

    PubMed  CAS  Google Scholar 

  135. Stefanova N, Mitschnigg M, Ghorayeb I, Diguet E, Geser F, Tison F, Poewe W, Wenning GK (2004) Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res 78:87–91

    PubMed  CAS  Google Scholar 

  136. Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, Wenning GK (2005) Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166:869–876

    PubMed  CAS  Google Scholar 

  137. Stefanova N, Reindl M, Poewe W, Wenning GK (2005) In vitro models of multiple system atrophy. Mov Disord 20(Suppl 12):S53–S56

    PubMed  Google Scholar 

  138. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK (2005) Animal models of multiple system atrophy. Trends Neurosci 28:501–506

    Google Scholar 

  139. Streit WJ, Sparks DL (1997) Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med 75:130–138

    PubMed  CAS  Google Scholar 

  140. Streit WJ, Walter SA, Pennell NA (1999) Reactive microgliosis. Prog Neurobiol 57:563–581

    PubMed  CAS  Google Scholar 

  141. Streit WJ, Sammons NW, Kuhns AJ, Sparks DL (2004) Dystrophic microglia in the aging human brain. Glia 45:208–212

    PubMed  Google Scholar 

  142. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964:288–294

    PubMed  CAS  Google Scholar 

  143. Sugama S, Wirz SA, Barr AM, Conti B, Bartfai T, Shibasaki T (2004) Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuroscience 128:451–458

    PubMed  CAS  Google Scholar 

  144. Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI (2005) Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Res 1052(2):119–129

    PubMed  CAS  Google Scholar 

  145. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E (2000) C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol (Berl) 99:296–304

    CAS  Google Scholar 

  146. Tanaka J, Maeda N (1996) Microglial ramification requires nondiffusible factors derived from astrocytes. Exp Neurol 137:367–375

    PubMed  CAS  Google Scholar 

  147. Tanji K, Imaizumi T, Yoshida H, Mori F, Yoshimoto M, Satoh K, Wakabayashi K (2001) Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta. Neuroreport 12:1909–1912

    PubMed  CAS  Google Scholar 

  148. Tanji K, Mori F, Imaizumi T, Yoshida H, Matsumiya T, Tamo W, Yoshimoto M, Odagiri H, Sasaki M, Takahashi H, Satoh K, Wakabayashi K (2002) Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathol Int 52:572–577

    PubMed  CAS  Google Scholar 

  149. Terada S, Ishizu H, Haraguchi T, Takehisa Y, Tanabe Y, Kawai K, Kuroda S (2000) Tau-negative astrocytic star-like inclusions and coiled bodies in dementia with Lewy bodies. Acta Neuropathol (Berl) 100:464–468

    CAS  Google Scholar 

  150. Togo T, Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K (2001) Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 184:71–75

    PubMed  CAS  Google Scholar 

  151. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VM (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44:415–422

    PubMed  CAS  Google Scholar 

  152. Unger ER, Sung JH, Manivel JC, Chenggis ML, Blazar BR, Krivit W (1993) Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol 52:460–470

    PubMed  CAS  Google Scholar 

  153. Urakami K, Mori M, Wada K, Kowa H, Takeshima T, Arai H, Sasaki H, Kanai M, Shoji M, Ikemoto K, Morimatsu M, Hikasa C, Nakashima K (1999) A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett 259:127–129

    PubMed  CAS  Google Scholar 

  154. van Rossum D, Hanisch UK (2004) Microglia. Metab Brain Dis 19:393–411

    PubMed  Google Scholar 

  155. van der Walt JM, Noureddine MA, Kittappa R, Hauser MA, Scott WK, McKay R, Zhang F, Stajich JM, Fujiwara K, Scott BL, Pericak-Vance MA, Vance JM, Martin ER (2004) Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet 74:1121–1127

    PubMed  Google Scholar 

  156. Vincent VAM, Tilders FJH, Van Dam AM (1997) Inhibition of endotoxin-induced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor-beta. Glia 19:190–198

    PubMed  CAS  Google Scholar 

  157. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180–182

    PubMed  CAS  Google Scholar 

  158. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol (Berl) 99:14–20

    CAS  Google Scholar 

  159. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763–1771

    PubMed  CAS  Google Scholar 

  160. Xie Z, Morgan TE, Rozovsky I, Finch CE (2003) Aging and glial responses to lipopolysaccharide in vitro: greater induction of IL-1 and IL-6, but smaller induction of neurotoxicity. Exp Neurol 182:135–141

    PubMed  CAS  Google Scholar 

  161. Yamada T, McGeer PL, McGeer EG (1991) Relationship of complement-activated oligodendrocytes to reactive microglia and neuronal pathology in neurodegenerative disease. Dementia 2:71–77

    Google Scholar 

  162. Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson’s disease are recognized by antibodies to complement proteins. Acta Neuropathol (Berl) 84:100–104

    CAS  Google Scholar 

  163. Yamazaki M, Arai Y, Baba M, Iwatsubo T, Mori O, Katayama Y, Oyanagi K (2000) Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 59:585–591

    PubMed  CAS  Google Scholar 

  164. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 74:278–285

    PubMed  CAS  Google Scholar 

  165. Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL (1993) Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease. Biochem Biophys Res Commun 192:246–251

    PubMed  CAS  Google Scholar 

  166. Yasuhara O, Schwab C, Matsuo A, Kim SU, Steele JC, Akiguchi I, Kimura J, McGeer EG, McGeer PL (1996) Midkine-like immunoreactivity in extracellular neurofibrillary tangles in brains of patients with parkinsonism-dementia complex of Guam. Neurosci Lett 205:107–110

    PubMed  CAS  Google Scholar 

  167. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, Lee VM (2005) Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847–859

    PubMed  CAS  Google Scholar 

  168. Zemke D, Majid A (2004) The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 27:293–298

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr. R.K.B. Pearce and Dr. L.B. Moran for their critical assessments in the preparation of this review.

Author information

Authors and Affiliations

  1. University Department of Neuropathology, Imperial College London and Hammersmith Hospitals Trust, Charing Cross campus, Fulham Palace Road, London, W6 8RF, UK

    Emilie Croisier & Manuel B. Graeber

Authors
  1. Emilie Croisier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel B. Graeber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel B. Graeber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croisier, E., Graeber, M.B. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol 112, 517–530 (2006). https://doi.org/10.1007/s00401-006-0119-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-006-0119-z

Keywords

Search

Navigation